1. Home
  2. EVM vs BMEA Comparison

EVM vs BMEA Comparison

Compare EVM & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EVM
  • BMEA
  • Stock Information
  • Founded
  • EVM 2002
  • BMEA 2017
  • Country
  • EVM United States
  • BMEA United States
  • Employees
  • EVM N/A
  • BMEA N/A
  • Industry
  • EVM Finance/Investors Services
  • BMEA Biotechnology: Pharmaceutical Preparations
  • Sector
  • EVM Finance
  • BMEA Health Care
  • Exchange
  • EVM Nasdaq
  • BMEA Nasdaq
  • Market Cap
  • EVM 220.1M
  • BMEA 65.8M
  • IPO Year
  • EVM N/A
  • BMEA 2021
  • Fundamental
  • Price
  • EVM $8.90
  • BMEA $1.94
  • Analyst Decision
  • EVM
  • BMEA Strong Buy
  • Analyst Count
  • EVM 0
  • BMEA 10
  • Target Price
  • EVM N/A
  • BMEA $22.30
  • AVG Volume (30 Days)
  • EVM 55.8K
  • BMEA 2.2M
  • Earning Date
  • EVM 01-01-0001
  • BMEA 07-30-2025
  • Dividend Yield
  • EVM 4.01%
  • BMEA N/A
  • EPS Growth
  • EVM N/A
  • BMEA N/A
  • EPS
  • EVM 0.20
  • BMEA N/A
  • Revenue
  • EVM N/A
  • BMEA N/A
  • Revenue This Year
  • EVM N/A
  • BMEA N/A
  • Revenue Next Year
  • EVM N/A
  • BMEA N/A
  • P/E Ratio
  • EVM $47.61
  • BMEA N/A
  • Revenue Growth
  • EVM N/A
  • BMEA N/A
  • 52 Week Low
  • EVM $7.67
  • BMEA $1.29
  • 52 Week High
  • EVM $9.59
  • BMEA $13.07
  • Technical
  • Relative Strength Index (RSI)
  • EVM 51.36
  • BMEA 49.92
  • Support Level
  • EVM $8.87
  • BMEA $1.58
  • Resistance Level
  • EVM $9.01
  • BMEA $2.01
  • Average True Range (ATR)
  • EVM 0.07
  • BMEA 0.15
  • MACD
  • EVM 0.01
  • BMEA 0.01
  • Stochastic Oscillator
  • EVM 60.71
  • BMEA 80.00

About EVM Eaton Vance California Municipal Bond Fund of Beneficial Interest $.01 par value

Eaton Vance California Municipal Bond Fund is an investment company with an objective to provide current income exempt from regular federal income tax, including alternative minimum tax, and, in state specific funds, taxes in its specified state. The company provides its solutions to individual investors, institutional investors, high net worth individuals, family office investors, and financial professionals. It offers a range of equity, income, and alternative strategies to institutional investors, both in the United States and internationally.

About BMEA Biomea Fusion Inc.

Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.

Share on Social Networks: